In its May 2019 network bulletin, UnitedHealthcare announced that, as of July 1, it will prefer the use of brand-name pegfilgrastim, Amgen’s Neulasta, over biosimilar options.
This article has been updated.
In its May 2019 network bulletin, UnitedHealthcare announced that, as of July 1, it will prefer the use of brand-name pegfilgrastim, Amgen’s Neulasta, over biosimilar options.
According to the bulletin, use of Neulasta Onpro (a presentation of the pegfilgrastim product in an on-body injector device) or Neulasta in a vial will be required before use of Mylan and Biocon’s biosimilar, Fulphila, or Coherus BioSciences’ biosimilar, Udenyca.
Additionally, UnitedHealthcare’s commercial plans will expand current prior authorization requirements to include the use of pegfilgrastim for any diagnosis. For current commercial plan members, existing authorizations will be honored through their end date, but providers are encouraged to begin prescribing the preferred Neulasta.
Also, as of August 1, brand-name filgrastim, Amgen’s Neupogen, will require prior authorization, as will its biosimilars: Pfizer’s Nivestym, Sandoz’s Zarxio, and Teva’s Granix (a follow-on product approved before the biosimilar pathway was established in the United States).
UnitedHealthcare also now prefers other reference products to biosimilars; brand-name infliximab, Remicade, is the preferred infliximab product. These changes represent a shift from UnitedHealthcare’s previous approach, under which Celltrion’s biosimilar, Inflectra, and Samsung Bioepis’ and Merck’s biosimilar, Renflexis, were preferred products and brand-name Remicade was not. A representative from UnitedHealthcare has told The Center for Biosimilars® in an email that, in October 2019, a change will take effect adding Inflectra to a preferred position along with Remicade. As such, beginning October 1, both Remicade and Inflectra will be preferred options for UnitedHealthcare commercial members.
Access to Inflectra and Renflexis now requires that a patient have tried and failed (or have had intolerance to) the reference drug. Physicians must attest that clinical response to a biosimilar would be expected to be superior to that of Remicade, or that a patient who did not tolerate Remicade would be expected to tolerate the biosimilar.
Notably, the practice of switching to a biosimilar in the case of treatment failure or intolerance to a reference drug is a practice that contradicts the European League Against Rheumatism’s recommendations, which indicate that switching to a different drug altogether would be appropriate in such a scenario, given the fact that biosimilars are not expected to have any clinically meaningful differences from their reference products.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.